1 2 3 4 245
Number of results: 4881

PDF print is not allowed for data more than 3000.Please search above for fewer data.

Date Company Compound Disease Type of agreement Therapeutic area Type of Information
2018-11-29 Voyager Therapeutics (USA-MA) Brammer Bio (USA - CA) Fujifilm Diosynth Biotechnologies (USA - NC) AAV-based gene therapies production - manufacturing Production agreement
2018-11-10 Abbvie (USA - IL) Sandoz (Switzerland)
  • intellectual property relating to Humira®
plaque psoriasis, rheumatoid arthritis, axial spondyloarthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, polyarticular juvenile idiopathic arthritis, active enthesitis-related arthritis, hidradenitis suppurativa, non-infectious uveitis licensing
  • biosimilar/monoclonal antibody/TNF alpha inhibitor. Adalimumab is a monoclonal antibody that binds specifically to TNF alpha and blocks its interaction with  cell surface TNF receptors. It is used to treat many conditions including rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis and plaque psoriasis.
Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Digestive diseases - Dermatological diseases Licensing agreement
2018-10-18 Abbvie (USA - IL) Fresenius Kabi (Germany) MSB11022 - biosimilar version of Humira® (adalimumab) licensing Autoimmune diseases – Inflammatory diseases - Rheumatic diseases - Dermatological diseases Licensing agreement
2018-10-18 Iovance Biotherapeutics (USA - CA) MaSTherCell (Belgium), a Orgenesis' subsidiary (USA - NY) tumor infiltrating lymphocyte (TIL)
  • manufaturing - bioproduction
Technology - Services Production agreement
2018-10-18 Xyphos Biosciences (USA - CA) The Parker Institute for Cancer Immunotherapy (USA - CA) universal CAR-T therapies based on convertibleCAR’® platform collaboration Cancer - Oncology Collaboration agreement
2018-10-17 Recombinetics (USA - MN) Mayo Clinic (USA - MN) regenerative stem cell therapies research - development - R&D Technology - Services - Regenerative medicine Research agreement
2018-10-16 Biomarin Pharmaceutical (USA - CA) Medivation (USA - CA), now Pfizer (USA - NY) talazoparib (BMN 673) metastatic breast cancer. product acquisition Cancer - Oncology Milestone
2018-10-16 Ziopharm Oncology (USA - MA) member of the board of directors nomination Cancer - Oncology Nomination
2018-10-15 Medivir (Sweden) nomination - restructuration Infectious diseases Restructuring
2018-10-15 Sarepta Therapeutics (USA - MA) Lysogene (France) LYS-SAF302 mucopolysaccharidosis type IIIA (Sanfilippo B syndrome) licensing Rare diseases - Genetic diseases Licensing agreement
2018-10-10 Ionis Pharmaceuticals (USA - CA) Roche (Switzerland) IONIS-FB-LRx complement-mediated diseases including geographic atrophy development Ophtalmological diseases Development agreement
2018-10-09 Iris Pharma (France) Keen Eye (France) artificial intelligence (AI) applications for bioimaging analysis ophtalmological diseases collaboration Ophtalmological diseases - Technology - Services Collaboration agreement
2018-10-09 ERS Genomics (Ireland) GenAhead Bio (Japan) CRISPR/Cas9 genome editing technology patents licensing Technology - Services Licensing agreement
2018-10-09 Ziopharm Oncology (USA - MA) Precigen (USA - MD) Sleeping Beauty licensing Cancer - Oncology Licensing agreement
2018-10-08 Sarepta Therapeutics (USA - MA) Paragon Bioservices (USA - MD) manufacturing platform for gene therapy programs manufacturing - bioproduction Rare diseases - Genetic diseases - Technology - Services Production agreement
2018-10-08 eTheRNA immunotherapies (Belgium) mRNA manufacturing facility opening of new premises Cancer - Oncology - Technology - Services Opening of new premises
2018-10-08 Vivebiotech (Spain) undisclosed European hospitals - undisclosed Norwegian company lentivirus cancers, undisclosed rare disease services contract Technology - Services Services contract
2018-10-08 Cytosen Therapeutics (USA - TX) member of the board of directors nomination Cancer - Oncology Nomination
2018-10-05 Oxford Biomedica (UK) Orchard Therapeutics (UK) lentiviral vectors for ex-vivo gene therapy products in primary immune deficiency disorders and inherited metabolic disorders adenosine deaminase severe combined immunodeficiency (ADA-SCID), mucopolysaccharidosis-IIIA (MPS-IIIA or Sanfilippo Syndrome type A), undisclosed follow-on indications. collaboration Rare diseases - Genetic diseases Licensing agreement
2018-10-05 Sarepta Therapeutics (USA - MA) Nationwide Children’s Hospital (USA - OH) AAV1 neurotrophin 3 (NT-3) gene therapy Charcot-Marie-Tooth (CMT) neuropathies including CMT type 1A licensing Rare diseases - Genetic diseases - Neuromuscular diseases Licensing agreement